[PDF][PDF] Cancer Treatment with Oncoshuttle
VN Pak - Cancer Sci Res, 2021 - scivisionpub.com
Oncofetal alpha-fetoprotein (AFP) activates in developing as well as in growing cancer cells.
It delivers polyunsaturated fatty acids through specific cell receptors. AFP-binding receptors …
It delivers polyunsaturated fatty acids through specific cell receptors. AFP-binding receptors …
α-fetoprotein-binding toxins and teratogens against cancer
VN Pak - Therapeutic Delivery, 2019 - Taylor & Francis
Conclusion Recombinant human AFP is close to becoming a registered drug [17]. Then it
could be provided to patients together with registered drugs-teratogens and AFP-binding …
could be provided to patients together with registered drugs-teratogens and AFP-binding …
Alpha-Fetoprotein Binds Toxins and Can Be Used to Treat Cancer
VN Pak - Medical Research Archives, 2022 - esmed.org
The inefficiency of the immune system to kill cancer cells leads to the disease. Like in
pregnancy, oncofetal proteins counteract the immune attack. Alpha-fetoprotein is an …
pregnancy, oncofetal proteins counteract the immune attack. Alpha-fetoprotein is an …
The receptor binding fragment of alpha-fetoprotein is a promising new vector for the selective delivery of antineoplastic agents
GA Posypanova, VA Makarov… - Journal of Drug …, 2013 - Taylor & Francis
The alpha-fetoprotein (AFP) binding protein, a putative AFP receptor, is a tumour marker that
is present on the surfaces of malignant cells. AFP enters cells through receptor-mediated …
is present on the surfaces of malignant cells. AFP enters cells through receptor-mediated …
An alpha-fetoprotein-maytansine conjugate for the treatment of AFP receptor expressing tumors.
IA Sherman, RJ Boohaker, K Stinson, P Griffin, W Hill - 2022 - ascopubs.org
e15056 Background: The alpha fetoprotein (AFP) receptor is an oncofetal antigen and a
novel target for cancer therapeutics. It is highly expressed on the surfaces of many cancers …
novel target for cancer therapeutics. It is highly expressed on the surfaces of many cancers …
523P AFP-maytansine conjugate: A novel targeted cancer immunotherapy
IA Sherman, R Boohaker, K Stinson… - Annals of …, 2021 - annalsofoncology.org
Background The alpha fetoprotein (AFP) receptor is an oncofetal antigen and a novel target
for cancer therapeutics, This receptor is highly expressed on the surface of common cancers …
for cancer therapeutics, This receptor is highly expressed on the surface of common cancers …
High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model
P Griffin, WA Hill, F Rossi, R Boohaker, K Stinson… - Cancer Cell …, 2023 - Springer
The alpha-fetoprotein receptor (AFPR) is a novel target for cancer therapeutics. It is
expressed on most cancers and myeloid derived suppressor cells (MDSCs) but generally …
expressed on most cancers and myeloid derived suppressor cells (MDSCs) but generally …
AFP-Inhibiting fragments for drug delivery: the promise and challenges of targeting therapeutics to cancers
B Lin, X Dong, Q Wang, W Li, M Zhu… - Frontiers in Cell and …, 2021 - frontiersin.org
Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug
resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the …
resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the …
[HTML][HTML] The possible drug for cancer and metastasis prevention
VN Pak - Future Drug Discovery, 2022 - Taylor & Francis
One in two people will be diagnosed with cancer in their lifetime in developed countries.
Prophylactics and early diagnostics are recommended to everyone. On the other hand, even …
Prophylactics and early diagnostics are recommended to everyone. On the other hand, even …
Efficacy and safety study of a novel alpha-fetoprotein (AFP)-maytansine conjugate in an ovarian xenograft model.
IA Sherman, W Hill, P Griffin, D Andrews, RJ Boohaker… - 2023 - ascopubs.org
e14570 Background: AFP receptor is an oncofetal antigen and a novel target for cancer
therapeutics. It is highly expressed on the surfaces of many cancers and Myeloid Derived …
therapeutics. It is highly expressed on the surfaces of many cancers and Myeloid Derived …